Canakinumab a Success in Systemic JIA, Study Confirms

(MedPage Today) -- Canakinumab (Ilaris) was effective in treating a majority of children with systemic juvenile idiopathic arthritis (JIA), a real-world Italian multicenter study found.
Among a cohort of 80 children with systemic JIA, 63.7% achieved...